Is biotech subprime pharma? Too much Phase II, not enough Phase III
This article was originally published in Scrip
Executive Summary
With big pharma facing a fall in revenues associated with the patent expiries of key blockbuster drugs coupled with a drying of its own R&D pipelines, it may be surprising that more biotech asset accumulation deals are not consummated. Closer examination of the pipelines of the biotech industry throws some light on why deal making has remained at a subdued rate.
You may also be interested in...
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Stock Scan April 2018: Pharma's Fizz Falls Flat
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.